USA - NASDAQ:NXGL - US65344E1073 - Common Stock
The current stock price of NXGL is 1.93 USD. In the past month the price decreased by -20.16%. In the past year, price decreased by -33.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.93 | 14.33B | ||
| SOLV | SOLVENTUM CORP | 12.78 | 13.16B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.58 | 10.22B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.66 | 5.21B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.18 | 3.72B | ||
| HAE | HAEMONETICS CORP/MASS | 15.54 | 3.59B | ||
| ICUI | ICU MEDICAL INC | 17.34 | 3.41B | ||
| XRAY | DENTSPLY SIRONA INC | 6.95 | 2.19B | ||
| UFPT | UFP TECHNOLOGIES INC | 28.26 | 1.88B | ||
| NEOG | NEOGEN CORP | 21.6 | 1.41B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.29B | ||
| EMBC | EMBECTA CORP | 5.06 | 864.48M |
NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-12-22. The company is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The firm operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
NEXGEL INC
2150 Cabot Blvd West,, Suite B
Langhorne PENNSYLVANIA US
Employees: 19
Phone: 12157028550
NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-12-22. The company is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The firm operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
The current stock price of NXGL is 1.93 USD. The price decreased by -4.46% in the last trading session.
NXGL does not pay a dividend.
NXGL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NEXGEL INC (NXGL) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
NEXGEL INC (NXGL) has a market capitalization of 15.58M USD. This makes NXGL a Nano Cap stock.
ChartMill assigns a fundamental rating of 3 / 10 to NXGL. NXGL has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NXGL reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 38.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.07% | ||
| ROE | -62.51% | ||
| Debt/Equity | 0.17 |
7 analysts have analysed NXGL and the average price target is 6.12 USD. This implies a price increase of 217.1% is expected in the next year compared to the current price of 1.93.
For the next year, analysts expect an EPS growth of 42.88% and a revenue growth 44.56% for NXGL